Efficacy and safety of i.v. alteplase therapy up to 4.5 hours after acute ischemic stroke onset

American Journal of Health-System Pharmacy

Volumn 67, Issue 13, 2010, Pages 1070-1074

  Otwell, Jenna L ^a   Phillippe, Haley M ^a   Dixon, Kelly S ^b  

^a AUBURN UNIVERSITY   (United States)

^b HUNTSVILLE HOSPITAL   (United States)

Author keywords

Alteplase; Dosage schedules; Geriatrics; Injections; Stroke; Thrombolytic agents; Toxicity

Indexed keywords

ALTEPLASE; PLACEBO; PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; DISABILITY; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL LITERATURE; MEDICAL SOCIETY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; EVIDENCE BASED MEDICINE; REVIEW; STROKE; TIME; UNITED STATES;

BRAIN ISCHEMIA; EVIDENCE-BASED MEDICINE; HUMANS; PLASMINOGEN ACTIVATORS; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77956620945     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090501     Document Type: Article

References (13)

1. American Stroke Association. Impact of stroke. www.strokeassociation.org/ presenter.jhtml?identifier=1033 (accessed 2010 Apr 26).
2. Adams HP, del Zoppo G, Alberts MJ et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke. 2007; 38:1655-711.
3. Albers GW, Amarenco P, Easton D et al. Antithrombotic and thrombolytic therapy: American College of Chest Physicians guidelines (8th edition). Chest. 2008; 133(suppl):630S-669S.
4. Activase (alteplase) product information. South San Francisco, CA: Genentech; 2005 Dec.
5. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333:1581-7.
6. Del Zoppo GJ, Saver JL, Jauch EC et al., on behalf of the American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009; 40:2945-8.
7. Wahlgren N, Ahmed N, Davalos A et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008; 372:1303-9.
8. Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359:1317-29.
9. Hacke W, Kaste M, Fieschi C et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274:1017-25.
10. Hacke W, Kaste M, Fieschi C et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998; 352:1245-51. (Pubitemid 28470336)
11. Clark WM, Wissman S, Albers GW et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - the ATLANTIS study: a randomized controlled trial. JAMA. 1999; 282:2019-26.
12. Clark WM, Albers GW, Madden KP et al. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Stroke. 2000; 31:811-6. (Pubitemid 30198420)
13. Davis SM, Donnan GA, Parsons MW et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008; 7:299-309.